Montagu Private Equity & Partners Group take majority stake in HTL Biotechnology
Context
This transaction marks the third leveraged buyout for HTL Biotechnology, with Montagu Private Equity entering into exclusive negotiations to acquire a majority stake from Bridgepoint. Partners Group joined Montagu as a co-investor in this operation, while the existing management team remains significantly involved in the capital. The strategic rationale for this LBO is to accelerate HTL,s transformation from a specialized hyaluronic acid producer into a diversified, global biopolymer platform. Under the previous ownership, the company significantly expanded its R&D capabilities, doubled its production capacity with a €50M industrial investment, and established a strong presence in the US and Chinese markets. Key to this new phase of growth is a major partnership with Eirion Therapeutics, positioning HTL as the exclusive manufacturer of a novel botulinum toxin using its proprietary fermentation process. Montagu intends to leverage its healthcare expertise to further the group,s internationalization and portfolio diversification, particularly in high-growth segments like tissue engineering. The acquisition is supported by a significant unitranche financing package, reflecting the strong cash-flow generation and premium positioning of the asset in the pharmaceutical supply chain.
In the past, HTL Biotechnology was acquired by Bridgepoint in 2018 as part of its expansion strategy.
HTL Biotechnology, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of Above 20x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in the late 20th century, HTL is a leading global biotechnology company specializing in the development, production, and purification of pharmaceutical-grade hyaluronic acid and other bio-sourced polymers. Based in Brittany, the company utilizes advanced fermentation and purification processes to supply high-purity ingredients to the global healthcare industry. Its value proposition is centered on technical excellence and the ability to provide customized molecular weights for sensitive medical applications, including dermatology for wrinkle filling, ophthalmology for cataract surgery, and rheumatology for joint treatments. HTL,s strategy focuses on continuous innovation through significant R&D investments and the expansion of its industrial capacities to maintain a leadership position in the high-end biopolymer market. By maintaining a discreet but critical role in the pharmaceutical supply chain, the company ensures that global medical device and pharma manufacturers have access to safe, natural, and highly effective components for life-changing medical treatments.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
Above 20x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with HTL Biotechnology
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2018 | BRIDGEPOINT | HTL BIOTECHNOLOGY | FRANCE | CDMO |
Other operations with Montagu Private Equity / Partners Group
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 05/2023 | TA ASSOCIATES / MONTAGU PRIVATE EQUITY | HARVEST | FRANCE | Financial Services / Banking |
| 10/2022 | PARTNERS GROUP | TELEPASS | ITALY | Fintech & Payments |
| 02/2022 | PARTNERS GROUP | FOREFRONT DERMATOLOGY | UNITED STATES | Outpatient Care |
| 01/2022 | PARTNERS GROUP | ATNORTH | ICELAND | Hosting / Datacenter |
| 11/2021 | PARTNERS GROUP | DIVERSITECH | UNITED STATES | Valves, Pumps & Taps |
| 07/2021 | MONTAGU PRIVATE EQUITY | INTECH MEDICAL | FRANCE | Implants & Prosthetics |
| 07/2021 | PARTNERS GROUP | PHARMATHEN | GREECE | CDMO |
| 01/2021 | MONTAGU PRIVATE EQUITY | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 07/2020 | PARTNERS GROUP | ROVENSA | PORTUGAL | Specialty Chemicals |
| 03/2020 | TETHYS INVEST / CPPIB (CANADA PENSION PLAN INVESTMENT BOARD) / MONTAGU PRIVATE EQUITY | GALILEO GLOBAL EDUCATION | FRANCE | Education Providers |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2022 | FRESENIUS | MABXIENCE | SPAIN | CDMO |
| 03/2022 | FRESENIUS | IVENIX | UNITED STATES | Diagnostic Equipment |
| 01/2022 | ANJAC BEAUTY & HEALTH | APOLLO HEALTHCARE CORP.. | CANADA | CDMO |
| 01/2022 | PERMIRA | KEDRION | ITALY | CDMO |
| 01/2022 | PERMIRA | BIO PRODUCTS LABORATORY (BPL) | UNITED KINGDOM | CDMO |
| 01/2022 | ARDIAN | BIOFARMA GROUP | ITALY | CDMO |
| 12/2021 | THE CARLYLE GROUP / GTCR | RESONETICS | UNITED STATES | Medical Devices |
| 12/2021 | WINNCARE | PHARMAOUEST INDUSTRIES | FRANCE | Medical Devices |
| 12/2021 | PLANMECA GROUP | KAVO DENTAL | GERMANY | Medical Devices |
| 12/2021 | INTEGER | OSCOR | UNITED STATES | Implants & Prosthetics |
REFERENCES
Valuation range: EV €1–10bn
EBITDA range: €50–100M
EV/EBITDA range: Above 20x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HTL Biotechnology by Montagu Private Equity / Partners Group are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: htl biotechnology
FAQ
What transaction does this page cover?
How was the acquisition of HTL Biotechnology by Montagu Private Equity valued, and what multiples were paid?
What was HTL Biotechnology’s EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?